Takeda Picks Next Big Thing In Immunotherapy: Gamma Delta T Cells
Executive Summary
Takeda is aiming to get ahead in what it believes is an emerging area with big potential in immunotherapy: gamma delta T-cells. It has signed a deal with GammaDelta Therapeutics that gives it a purchase option on the UK-based, Abingworth-backed start-up. GammaDelta's CEO, former GSK executive Paolo Paoletti, and the head of Takeda's external innovation center, Dan Curran, spoke to Scrip.
You may also be interested in...
Asia Deal Watch: I-Mab Partners With Sinopharm As It Readies First Regulatory Filing
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
Takeda's Deal Flurry Set To Wane
Takeda's reorganization and the focusing of its R&D on specialty medicines in three sectors is shifting to the next stage, with products moving through its pipeline; the company has lifted its financial outlook at the six-month stage, but is wary of the emergence of US generic competition to Velcade later this year.
Start-Up Quarterly Statistics: Private And Public Firms Were Prolific Fundraisers
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.